SCHEMBL257413

SCHEMBL257413

CCCc1nn(Cc2ccccc2)c2cc(OCCN(Cc3ccccc3)Cc3ccccc3)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
KCNH2 Q12809 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GUCY1B2 O75343 1/20 0.40
CHRM2 P08172 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD1 P21728 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
GUCY1A2 P33402 1/20 0.40
ADRA1A P35348 1/20 0.40
OPRM1 P35372 1/20 0.40
DRD3 P35462 1/20 0.40
SLC6A3 Q01959 1/20 0.40
GUCY1A1 Q02108 1/20 0.40
GUCY1B1 Q02153 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240917 0.82 SCN8A (0.50) MAOBKDM4EADRA1ADRD3ACHE
SCHEMBL2239649 0.80 GRM2 (0.35) MAOBCYP1A2CYP2D6KCNH2CYP2C9
SCHEMBL2239656 0.80 GRM2 (0.35) MAOBCYP1A2CYP2D6KCNH2CYP2C9
SCHEMBL176993 0.74 SLC16A3 (0.46) PDE5ASLC16A3ACHE
SCHEMBL30728962 0.73 SLC16A3 (0.55) CYP1A2CYP2D6KCNH2KDM4EGUCY1B2
SCHEMBL11897109 0.71 MAOB (0.45) MAOBABCB1ABCC1ABCG2ACHE
SCHEMBL177398 0.71 MAOB (0.47) MAOBPOLBABCB1ABCC1ABCG2
SCHEMBL177355 0.69 HCRTR2 (0.47) MAOBABCB1ABCC1ABCG2ATM
SCHEMBL2307921 0.68 MAOB (0.43) MAOBKDM4EABCB1ABCC1ABCG2
SCHEMBL11897265 0.67 MAOB (0.44) MAOBKDM4EABCB1ABCC1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
EP-2345644-A1 INDAZOLE COMPOUND Asahi Kasei Pharma Corporation (JP) 2011-07-20 EP disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
WO-2010041569-A1 INDAZOLE COMPOUND 旭化成ファーマ株式会社 (JP) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160256-A1 INDAZOLE COMPOUNDS GPR119, ADRB1, ADRA1A MAOB 411/4885CYP1A2 130/4885CYP2D6 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.